Association between TGFBR1*6A and osteosarcoma: A Chinese case-control study

<p>Abstract</p> <p>Background</p> <p>TGFBR1*6A is a common hypomorphic variant of transforming growth factor β receptor 1 (TGFBR1). TGFBR1*6A is associated with an increased cancer risk, but the association of this polymorphism with osteosarcoma remains unknown. We have measured the frequency of TGFBR1*6A variants in osteosarcoma cases and controls.</p> <p>Methods</p> <p>Our case-control study is based on 168 osteosarcoma patients and 168 age- and gender-matched controls. Blood samples were obtained and the TGFBR1*6A variant determined by PCR amplification and DNA sequencing. The odds ratio (OR) and 95% confidence interval (95% CI) for the TGFBR1*6A polymorphism were calculated by unconditional logistic regression, adjusted for both age and gender. Three models - dominant, additive and recessive - were used to analyze the contribution of the TGFBR1*6A variant to osteosarcoma susceptibility.</p> <p>Results</p> <p>Heterozygotic and homozygotic TGFBR1*6A variants represented 50.4% and 6.0% of the 168 cases, whereas the controls had 18. 5% and 1.3%, respectively. ORs for homozygosity and heterozygosity of the TGFBR1*6A allele were 4.6 [95% CI, 2.33-7.97] and 2.9 [95% CI, 1.59-5.34] in the additive model. There were significant increases in the TGFBR1*6A variants in osteosarcoma cases compared to control in all 3 models. Further analysis showed that TGFBR1*6A genotypes were not associated with gender, age, or tumor location. However, TGFBR1*6A was significantly associated with less metastasis.</p> <p>Conclusions</p> <p>TGFBR1*6A, a dominant polymorphism of TGFBR1, is associated with increased susceptibility and metastasis spread of osteosarcoma.</p

2-(5-Bromo­pent­yl)-4-chloro-5-[2-(4-meth­oxy­phen­yl)ethyl­amino]­pyridazin-3(2H)-one

The asymmetric unit of the title compound, C18H23BrClN3O2, consists of two mol­ecules which exhibit different conformations of the pentyl chains [C—C—C—C torsion angles of −60.4 (4) and 175.8 (3)°]. The crysal packing exhibits a chain structure, generated through the O atom of the pyridazinone forming a hydrogen bond with the N—H group of an adjacent mol­ecule

catena-Poly[[[diaqua­iron(II)]-μ-pyridine-2,5-dicarboxyl­ato-[tetra­aqua­iron(II)]-μ-pyridine-2,5-dicarboxyl­ato] tetra­hydrate]

In the crystal structure of the title compound, {[Fe2(C7H3NO4)2(H2O)6]·4H2O}n, there are two types of coordination for the FeII atoms. One FeII atom is in a distorted octa­hedral N2O4 environment, with two chelating rings from the pyridine­dicarboxyl­ate ligands and two O atoms from the water mol­ecules, while the other is in a distorted octa­hedral O6 environment with two O atoms from the pyridine­dicarboxyl­ate ligands and four O atoms from the water mol­ecules. Both FeII atoms lie on crystallographic centers of symmetry. The complex possesses an infinite chain structure running along the [101] direction. These chains are inter­connected by the uncoordinated water mol­ecules through O—H⋯O hydrogen bonds